Quick Answer
Adaptive Biotechnologies Corp reported Total Assets of $512.74 million for the year ending 2025.
- Adaptive Biotechnologies Corp showed a decrease of -4.9% in Total Assets from 2024 to 2025.
- This data is from Adaptive Biotechnologies Corp's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $601.40 million | Q3 2019: $917.39 million | Q1 2020: $874.89 million | Q2 2020: $854.82 million | Q3 2020: $1.10 billion | Q1 2021: $1.07 billion | Q2 2021: $1.03 billion | Q3 2021: $992.61 million | Q1 2022: $858.19 million | Q2 2022: $806.63 million | Q3 2022: $884.21 million | Q1 2023: $791.46 million | Q2 2023: $764.54 million | Q3 2023: $717.68 million | Q1 2024: $620.32 million | Q2 2024: $584.87 million | Q3 2024: $558.51 million | Q1 2025: $510.85 million | Q2 2025: $496.64 million | Q3 2025: $490.61 million.
- Over the full 8 years of available data (2018 to 2025), Adaptive Biotechnologies Corp's Total Assets has grown by 54.1%.
- Historical annual values: Fiscal year 2025: $512.74 million | Fiscal year 2024: $539.38 million | Fiscal year 2023: $661.13 million | Fiscal year 2022: $856.62 million | Fiscal year 2021: $923.34 million | Fiscal year 2020: $1.12 billion | Fiscal year 2019: $912.30 million | Fiscal year 2018: $332.69 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: